has been shown to exert various electrophysiological actions in the spinal cord [1, 3, 4] , the cerebellum [5] , and the cerebral cortex [1] . The potassium stimulation of neurons in brain slices [6] and of cortical synaptosomes [7] released radiolabeled proline. A proline transporter cloned by cDNA was also found to be expressed in rat brain [8] .
Abstract: L-Glutamate has been considered to be a neurotransmitter in the nucleus tractus solitarius (NTS) of the afferent baroreflex pathway, though this has not yet been decisively shown. A bolus injection of a neurotransmitter candidate amino acid L-proline into the cisterna magna and that of L-glutamate shows the same pressor action in the freely moving rat, but the actual nuclei responding L-proline remain undetermined. Besides L-glutamate, L-proline might be another candidate amino acid in the NTS. The present study was therefore performed to characterize the circulatory action of L-proline injected into the NTS where responses to glutamate in the anesthetized rat had already been shown. The NTS was first determined as a site on the dorsal surface of the medulla where a microinjection of Lglutamate decreased arterial pressure and heart rate. Microinjected L-proline (1.65 to 13.2 nmol, 33 nl) into the NTS decreased arterial pressure and heart rate in a dose-dependent manner. The injection of a mixed solution (66 nl) of kynurenate, an ionotropic excitatory amino acid receptors antagonist (1.32 nmol), and L-proline (6.6 nmol) into the NTS abolished the depressor and bradycardic actions with L-proline alone (6.6 nmol, 66 nl). However, a mixture of an increased concentration of kynurenate (6.6 nmol) with glutamate augmented the actions seen with glutamate alone (0.66 nmol, 66 nl). D-Proline (13.2 nmol, 66 nl), the optic isomer of L-proline, produced no change in arterial pressure or heart rate, suggesting that the actions of L-proline in the NTS were optically specific. The results indicate that L-proline but not D-proline induces its depressor and bradycardic actions through ionotropic excitatory amino acid receptors in the NTS of the anesthetized rat. L-Proline may become a candidate transmitter of baroreceptor information in the NTS. [ [15] . Injections of L-proline [10] and of L-glutamate [16] into the cisterna magna of the conscious rat produced the same pressor action through the release of vasopressin. Kynurenate abolished the response to L-proline and attenuated the response to glutamate, but the response remained, suggesting that L-proline is a potential endogenous neurotransmitter for iEAA receptors in the vicinity of the cisterna magna [11] . These results prompted me to hypothesize that L-proline might be another candidate neurotransmitter amino acid in the NTS. To test this hypothesis, I adopted the same protocol used for animals under anesthesia as that proposed by Talman et al. [13] . Glutamate application to the NTS of the anesthetized rat has been shown to induce a decrease in arterial blood pressure (ABP) [13] . The restricted application of L-proline into the NTS under anesthesia could produce a depressor action in contrast to the pressor action caused by intracisternally injected L-proline in the conscious rat, as was the case with glutamate. The present study therefore characterized the actions of L-proline in the NTS of the anesthetized rat and compared these findings with actions of glutamate to determine (1) if Lproline has the same depressor and bradycardic actions as L-glutamate does, and (2) if kynurenate blocks the cardiovascular actions of L-proline and glutamate in this experimental protocol. Furthermore, because the action of intracisternally applied L-proline was found to be optically specific in a previous study on conscious rats [10] , the action of L-proline's optic isomer D-proline on the NTS was also tested.
METHODS
All protocols and surgical procedures used in this study were performed in accordance with the "Guiding Principles for the Care and Use of Animals in the Field of Physiological Sciences," published by the Physiological Society of Japan. Operation and preparation of animals. Experiments were conducted on male Wistar rats, weighing 300-370 g. The animals were anesthetized with urethane (1.0-1.3 g/kg, I.P.), and supplemental doses were given intermittently to maintain anesthesia. A tracheotomy and an insertion of a tracheal cannula coated with atropine sulphate ointment (Santen, Japan) were performed, and the femoral artery was cannulated with polyethylene tubing (PE50) for the monitoring of ABP via a pressure transducer. ABP and heart rate (HR) derived from blood pressure waves were recorded on a pen writing oscillograph (Nihon Kohden, Japan). The animals were placed in a prone position on a stereotaxic frame (Narishige, Japan) with the incisor bar set to 11 mm below the level of the interaural line, and artificially ventilated by a rodent respirator (Shinano, Japan), with tidal volume set at 1.0 ml/100 g body weight at rates of 65-75 cycles/min. A microscope used to observe the experimental area revealed that the dorsal surface of the medulla oblongata was exposed at the level of the calamus scriptorius through a partial occipital craniotomy. Rats were immobilized by an I.V. infusion of pancuronium bromide (Sankyo, Japan) at a rate of 0.5 mg/kg/h. After the induction of neuromuscular blockade, the adequacy of the anesthesia was assessed according to the stability of ABP and the absence of a pressor response to a firm toe pinch. The rectal temperatures of the rats was maintained at 37Ϯ0.5°C by a heating mat.
Preparation for microinjections. For microinjections of solutions into the NTS, a glass micropipette with a tip of 20-30 m outside diameter was prepared and mounted on a micromanipulator. The other end of the micropipette was attached via a polyethylene tube (PE20) to a Hamilton microsyringe. Amino acids were dissolved in artificial cerebrospinal fluid (aCSF) [17] . By changing from an initial solution to another solution using the same micropipette, repeated injections of several kinds of aminoacid-containing solutions were made into the site responding to glutamate or L-proline. The microinjection experiments were performed by observing the exposed area of the brain with the aid of the microscope. Kynurenate stock solution (0.5 M) was prepared by dissolving kynurenic acid in 0.4 N NaOH, which was then neutralized with HCl solution. With this stock solution and aCSF, mixed solutions of L-proline (6.6 nmol) and kynurenate (1.32 nmol) in 66 nl aliquots, and L-glutamate (0.66 nmol) and kynurenate (6.6 nmol) in 66 nl aliquots were prepared.
Experiments. Protocol 1: Dose-response relationship of L-proline. The NTS was defined in the present study as the point in the assumed vicinity of the NTS where Lglutamate application decreased ABP and HR. L-Glutamate (0.33 nmol, 33 nl) was first unilaterally applied into the region of the NTS, the initial coordinates of which were taken to be 0.5 mm rostral and 0.5 mm lateral to the calamus scriptorius and 0.5 mm in depth from the medullary dorsal surface. On occasions when the depressor and bradycardic actions of L-glutamate were not obtained, several points around the initial coordinates were retested until an appropriate response was achieved. L-Proline and the vehicle solution (aCSF) were then injected into the same point in the NTS defined with L-glutamate. L-Proline was injected repeatedly at 10 min intervals, since no decay of the response was observed (as described in RE-SULTS).
Protocol 2: The effect of kynurenate. Kynurenate solution (1.32 nmol) alone produced no changes in ABP or HR. In pilot tests, the depressor and bradycardiac actions of L-proline (6.6 nmol, 66 nl) were completely blocked when co-injected with one-fifth concentration of kynurenate (1.32 nmol). In contrast, the actions of L-glutamate (0.66 nmol, 66 nl) were augmented when it was applied in conjunction with kynurenate (1.32 or 6.6 nmol) in a separate group of animals. The depressor action of L-proline was restored 40 min after inhibition by and then removal of kynurenate. Therefore the following protocol was designed to reduce the number of animals sacrificed for experiments: After determination of an active site for L-proline (6.6 nmol, 66 nl), a series of solutions ((1) a mixed solution of kynurenate and L-proline, (2) L-proline (6.6 nmol), (3) L-glutamate (0.66 nmol), and (4) another mixed solution of kynurenate and L-glutamate) were successively injected into the same active site at intervals in excess of 10 min once ABP and HR had stabilized.
Protocol 3: Action of D-proline. In pilot tests, Dproline (3.3 to 26 nmol) induced no depressor and bradycardic actions, but evoked small increases in ABP and HR at higher doses. After obtaining an active point for L-proline (6.6 nmol, 66 nl) action in the NTS, a twofold concentration of D-proline (13.2 nmol), and another bolus L-proline (6.6 nmol) were successively applied at intervals of greater than 10 min.
RESULTS

The dose-response relationship of L-proline
Injection of L-proline into the NTS induced depressor and bradycardic actions similar to that seen with glutamate. Means and standard deviations (meanϮ SD) of changes in ABP and HR were Ϫ30.9Ϯ2.6 and Ϫ8.1Ϯ1.4% for seven repeated injections at 10 min intervals of L-glutamate (0.66 nmol, 66 nl) into the NTS of one rat. The corresponding values for L-proline (6.6 nmol, 66 nl) in a different animal were Ϫ40.4Ϯ3.2 and Ϫ15.7Ϯ5.6% for ABP and HR, respectively. There was no decay of response amplitude during repeated injections of either amino acid. L-Proline evoked no change in the ABP and HR when the injection point was laterally moved less than 50 m from the glutamate sensitive point; thus the reactive point to L-glutamate and L-proline was judged to be the same. Figure 1 shows the relationship between doses of L-proline (1.65-13.2 nmol, 33 nl) and decreases in ABP and HR when L-proline was injected into the NTS of seven rats. The vehicle solution (aCSF) evoked no changes in ABP and HR. L-Proline injected into the NTS evoked depressor and bradycardic actions in a dose-dependent manner. L-Glutamate (0.33 nmol, 33 nl) also produced decreases in ABP (Ϫ30Ϯ6.6%) and HR (Ϫ6.8Ϯ3.1%). The values of ABP and HR (nϭ42 each) before repeated injections were 86Ϯ8.7 mmHg (ABP) and 366Ϯ32 beats/ min (HR). Table 1 summarizes data obtained when kynurenate was co-injected with L-proline or L-glutamate. The depressor and bradycardic actions of L-proline (6.6 nmol) were completely blocked when a one-fifth concentration of kynurenate (1.32 nmol) was simultaneously applied. In contrast, the actions of glutamate (0.66 nmol) were significantly augmented, rather than inhibited, by the co-injection of a tenfold higher concentration of kynurenate (6.6 nmol). The recovery times to respond to L-proline alone after kynurenate co-injection varied widely. In six rats, L-proline took 20-45 min to obtain the same degree of circulatory actions as a previous injection of L-proline alone. In these rats, the intermittent injections of L-proline gradually induced depressor and bradycardic actions as the recovery time progressed. In one exceptional rat, however, L-proline evoked no changes in either ABP or HR even 100 min after the mixture injection, but successive injections of L-glutamate were effective in reducing ABP and HR. Several injections of L-proline over a 100 min period were performed in this rat, but induced no changes to the measured parameters. Table 2 summarizes the results obtained when Dproline was applied to the NTS. Although L-proline (6.6 nmol) induced significant changes in ABP and HR, twofold higher concentrations of D-proline (13.2 nmol) evoked none.
The effects of kynurenate on the actions of Lproline and L-glutamate
The action of D-proline in the NTS
DISCUSSION
The present study has demonstrated for the first time that the neurotransmitter candidate amino acid L-proline evoked depressor and bradycardic actions when injected into the NTS of urethane-anesthetized rats. The central action of L-proline was optically specific and was inhibited by the iEAA receptor antagonist kynurenate. Therefore, L-proline was likely to have acted upon iEAA receptors in the NTS.
The dose of L-proline (3.3 nmol) required to induce the same degree of changes (Ϫ30%) in ABP was 10 times higher than that of L-glutamate (0.33 nmol) (Fig. 1) . A simple explanation for this large difference in dose potency could be a low affinity of L-proline to its likely receptor, compared with that of L-glutamate. L-Glutamate activates both iEAA and metabotropic EAA (mEAA) receptors in the NTS to induce its depressor actions [18, 19] . When iEAA receptor activity was blocked by kynurenate, the actions of glutamate were augmented (Table 1) probably because of mEAA receptor activation. The depressor action of glutamate via mEAA receptors, besides its actions on iEAA receptors, could therefore be a further cause for the large observed difference between L-glutamate and Lproline in their required doses. It is also notable that glutamate injection into the NTS evokes different changes in several regional vascular beds [20] . Therefore a third possible explanation for the large difference in L-glutamate and L-proline doses used is the different effects on regional vascular resistances produced by either amino acid. L-Proline might have induced the changes in regional vascular resistances to minimize the total peripheral resistance. A final explanation is that of a possible high uptake ability of a proline transporter [8] , which may require higher doses of L-proline to elicit the observed cardiovascular actions.
As for the effect of kynurenate on the depressor ac- 
The values are meanϮSD. ABP, arterial blood pressure; HR, heart rate. ** and * pϽ0.01 and pϽ0.05 compared with values of glutamate by paired t-test. See text, protocol 2 in METHODS and RESULTS. † The data of six rats in which the responses to L-proline gradually recovered by 45 min after the previous injections. One rat was not responsive to L-proline injection even 100 min after the previous mixture injection, but it was responsive to the next injection of glutamate. The data from this rat were excluded from the column. The values in the parentheses are basal ABP (mmHg) and HR (beats/min) prior to injections. 
The values are meanϮSD. ABP, arterial blood pressure. HR, heart rate. The values in parentheses are basal ABP (mmHg) and HR (beats/min) prior to injections. † It took 20 min for variables in one rat to recover to original levels. tion of glutamate, several studies have shown different results [15, 18, 19, [21] [22] [23] ranging from complete [21] , partial [22, 23] , or no inhibition [15] , to augmentation [18, 19] . These studies adopted technically difficult injection procedures to aim and apply different agonist and antagonist solutions into exactly the same pinpoint active site, using (1) multibarrel pipettes all with wide tips, or (2) one micropipette by successive injection, possibly causing some discrepancy in induced responses. In the present study, mixed solutions containing both agonist and antagonist were injected into the likely active site. The results showed augmentation by kynurenate of the depressor and bradycardic actions of glutamate alone (Table 1) , which is consistent with the data by Gordon's group [18, 19] .
This augmented effect of glutamate with kynurenate may be explained speculatively at the level of neuronal interaction. In this way glutamate moderately activates iEAA receptors on the cell body of neuron A and markedly activates mEAA receptors on the cell body of another putative neuron B. Signals from neurons A and B are converted to inhibitory signals in pathways finally connecting to a vascular sympathetic neuron. Neuron B, with its mEAA receptors, then receives a putative inhibitory neuron C, such as an interneuron, on the cell body on which iEAA receptors are distributed. Glutamate application to this unit would activate all three types of receptors, with the result that the inhibitory neuron C with iEAA receptors would attenuate the inhibitory action of neuron B. In the situation of an iEAA receptor blockade with kynurenate, mEAA receptors on neuron B alone would be markedly activated because of the absence of inhibition from neuron C, possibly resulting in augmentation of the output depressor action. PawloskiDahm and Gordon [19] have already reported the depressor response to an mEAA receptor agonist. If the inhibitory neuron with mEAA receptors finally connecting to the vascular sympathetic neurons were to be identified, this hypothesis would be upheld.
In previous studies [9] [10] [11] , an intracisternal injection of L-proline induced pressor action in conscious freely moving rats, which is an effect opposite to that seen in the present study for rats maintained under urethane anesthesia. One important difference between the previous and present studies is the use of anesthesia. General anesthetics augment the function of GABA A receptors by prolonging the open time of chloride channels [24] and would modify the state of the neuronal circuitry controlling arterial pressure compared with that seen in the conscious state. The arterial pressure could be reversed under anesthesia if GABA A receptors are involved in the neuronal circuitry for arterial pressure. Another explanation is that nuclei besides NTS, which are sensitive to L-proline, might modify the depressor action of L-proline on the NTS to a pressor action. The distribution of dye injected into the cisterna magna highlights the possibility of the other active sites for an L-proline effect [12] , such as the caudal and rostral ventrolateral medulla [25] . The rostral ventrolateral medulla sending axons to the intermediolateral column is the final common pathway for the generation of basal sympathetic tone and is related to the caudal ventrolateral medulla, the NTS, and other nuclei involved in cardiovascular control [25] . The interaction between several acting nuclei could convert the depressor action of the NTS into a pressor action.
Talman et al. [13] first suggested L-glutamate as a neurotransmitter in the NTS responsible for the baroreflex. However, Talman later reported that a prior injection of kynurenate completely blocked the baroreceptor-heart rate-reflex, but did not block the action of glutamate injected into the NTS [15] . Because of this discrepancy, the role of the neurotransmitter glutamate in the afferent baroreflex pathway has not yet been decisively elucidated [14] . It is suggested that an EAA or EAA analog other than glutamate may be the neurotransmitter of baroreceptor information in the NTS [18] . Because the actions of Lproline were completely blocked by a co-injection of kynurenate in the present study, L-proline may serve as one of the other candidate neurotransmitters in the NTS.
Kynurenate abolished the depressor and bradycardiac actions of L-proline, but it augmented those of Lglutamate in the NTS of anesthetized rats. I have previously shown that kynurenate completely inhibited the pressor action of L-proline, but that the actions of L-glutamate injected into the cisterna magna of the conscious rat remained [11] . Although experimental conditions and circulatory actions between the previous and present studies were quite different, the mode of the central blocking effect of kynurenate was the same for the action of L-proline. Taken together, the neurotransmitter candidate L-proline [1] [2] [3] would have a special role in kynurenate-sensitive receptors, possibly iEAA receptors, for the central control of the cardiovascular system.
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